Adecatumumab (MT201) is a recombinant
human IgG1
monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (
EpCAM - CD326), with the intent to trigger
antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by
Amgen.[1]
Adecatumumab has been used in clinical studies of treatment in colorectal,
prostate[2] and
breast cancers.[3] Phase II results were published in 2010.[4]
^Oberneder R, Weckermann D, Ebner B, Quadt C, Kirchinger P, Raum T, et al. (October 2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". European Journal of Cancer. 42 (15): 2530–8.
doi:
10.1016/j.ejca.2006.05.029.
PMID16930989.